retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 What Is (RETA)? The Explained What Is Retatrutide? The Triple

In March 2026, the FDA sent warning letters to 30 telehealth companies for illegally marketing compounded GLP-1 drugs

Khera A, Powell-Wiley TM

GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

The BALANCE Model will empower more Americans to live healthier lives by expanding access to GLP-1s that have shown to be a powerful tool against the development of diseases, such as diabetes, cardiovascular disease, and other metabolic conditions, which can negatively affect a persons long-term health, CMMI Director Abe Sutton said in the press release

Reason one: potential clinical benefits The clinical argument goes like this